敏度优化的TCR-T细胞向KRAS新抗原,用于强大的癌症清除和瘤微环境重塑
Zhaoduan Liang1,2,3, Fengqiong Guan3, Bingling Wu3
1Bioland Laboratory, Guangzhou, Guangdong, China.
Frontiers in immunology
|February 11, 2026
概括
研究人员开发了一种改进的T细胞受体 (TCR3),准KRAS新抗原,显示出增强的抗瘤活性和免疫细胞招募. 这种针对KRAS的免疫疗法有望提高癌症治疗的疗效和安全性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 克拉斯新抗原是有前途的癌症标,但目前的免疫疗法面临着有效性和通用性的挑战.
- 目前没有KRAS新抗原向免疫产品被批准用于临床使用.
研究的目的:
- 开发和评估一种新的T细胞受体 (TCR) 突变,用于增强KRAS新抗原向癌症免疫疗法.
- 评估工程TCR的疗效,特异性和瘤微环境相互作用.
主要方法:
- 隔离了一个自然的人类T细胞受体 (TCR0) 识别KRAS G12V新抗原.
- 设计了一种突变的TCR (TCR3),以改善T细胞的反应和瘤细胞的杀死.
- 评估了TCR3-T细胞的活力,特异性,抗瘤活性 (体外和体内),以及免疫微环境调节.
主要成果:
- TCR3-T细胞表现出优化激烈性和强大的抗瘤反应对抗KRAS G12V表达瘤细胞系.
- TCR3-T细胞表现出特定杀死瘤细胞,包括表达PD-L1的瘤细胞,没有观察到对正常细胞的毒性.
- 改造的T细胞对免疫抑制因素 (IDO,TGF-β) 产生了抵抗力,并通过化学因子促进了免疫细胞的透.
结论:
- 设计的TCR3显示了KRAS新抗原向免疫治疗的巨大潜力.
- TCR3可以克服癌症免疫逃生机制,提高临床有效性和安全性.
- 进一步开发TCR3可能会导致针对KRAS突变癌症的新疗法策略.
相关概念视频
Affinity and Avidity
39.2K
Overview
39.2K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Nucleosome Remodeling
11.3K
Nucleosomes are the basic units of chromatin compaction. Each nucleosome consists of the DNA bound tightly around a histone core, which makes the DNA inaccessible to DNA binding proteins such as DNA polymerase and RNA polymerase. Hence, the fundamental problem is to ensure access to DNA when appropriate, despite the compact and protective chromatin structure.
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
11.3K
Cancer Stem Cells and Tumor Maintenance
6.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Bone Remodeling
40.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.5K


